Antirheumatic medicine from Astrapharm – Melsi

More than 23 million people suffer from rheumatoid arthritis, a chronic inflammatory disease that affects the joints and various body organs and systems (lungs, kidneys, skin, eyes, cardiovascular system)*.

Today, on 2nd February, World Rheumatoid Arthritis Awareness Day, we recall that the disease affects able-bodied people aged between 20 and 50 years. At the same time, women are affected 2.5 times more often than men.

Pain, stiffness and swelling in the joints significantly impair the quality of life of such patients, who must therefore take long-term symptomatic treatment to alleviate their condition.

For this purpose, the pharmaceutical company Astrapharm produces Melcy, a non-steroidal anti-inflammatory and anti-rheumatic drug.

Meloxicam in Melsi has analgesic, antipyretic and analgesic effects by inhibiting the enzymatic activity of cyclooxygenase-2 (COX-2), which takes part in the biosynthesis of prostaglandins in the inflamed area.

It is this mechanism of action that significantly reduces the risk of gastrointestinal complications, which is a significant advantage for rheumatoid arthritis patients.

Melcy is available in the form of tablets containing 7.5 or 15 mg Meloxicam no. 20.

The product is prescribed by a doctor only and is available with a prescription.

Astrapharm – the art of helping people!

*World Health Organization, The Global Burden of Disease Report (Table 7, page 32) 2004